RXi Pharmaceuticals Corp Share Price Nasdaq
Equities
US74979C3034
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 33.69L 28Cr |
---|---|---|---|---|---|
Net income 2024 * | -90L -75Cr | Net income 2025 * | 4.7Cr 392.44Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.4
x | P/E ratio 2025 * |
0.19
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.41% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/12/19 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/17/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/12/19 |
Director/Board Member | 73 | 02/22/02 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/13/18 |
1st Jan change | Capi. | |
---|---|---|
+29.03% | 4.82TCr | |
-0.10% | 4.17TCr | |
+43.45% | 4.1TCr | |
-5.26% | 2.88TCr | |
+11.48% | 2.56TCr | |
-22.74% | 1.9TCr | |
+9.06% | 1.29TCr | |
+30.01% | 1.2TCr | |
-1.51% | 1.18TCr |